Skip to main content
OpenTrials
Completed

NCT Number: NCT04388527

COVID-19 Convalescent Plasma for Mechanically Ventilated Population

The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it can improve patients' health when they are sick with COVID-19.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

About this study

This open-label, single arm, phase 1 trial will assess the safety and efficacy of convalescent plasma in severely ill, mechanically ventilated participants with pneumonia due to COVID-19. This study will enroll adults 18 years old and older, including pregnant women. A total of 50 eligible participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19. Participants will receive convalescent plasma on Study Day 1 in addition to standard of care. Participants will be assessed daily while hospitalized and then on Study Days 15, 22, 29, and 60. All participants will undergo a series of safety, efficacy, and laboratory assessments. Blood samples will be collected on Days 1 (prior to plasma administration), 3, 5, 8, 11, 15, 29, and 60. Oropharyngeal or endotracheal samples will be collected on Days 1 (prior to plasma administration), 3, 5, 8, 11, and 15.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult ≥18 years of age
  • Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other authorized or approved assay in any specimen collected within 72 hours prior to enrollment. Note - An exception must be requested to the Sponsor if≥72 hours since positive test.
  • Hospitalized, on invasive mechanical ventilation or ECMO, consistent with a clinical status assessment 8-point ordinal scale severity score of 7.
  • Documentation of pneumonia with radiographic evidence of infiltrates by imaging (e.g., chest x-ray or CT scan).
  • Patient or proxy is willing and able to provide written informed consent and comply with all protocol requirements.

Exclusion criteria

  • Contraindication to transfusion (e.g., severe volume overload, history of severe allergic reaction to blood products), as judged by the investigator.
  • Clinical suspicion that the etiology of acute illness (acute decompensation) is primarily due to a condition other than COVID-19
  • Receipt of other investigational therapy as a part of another clinical trial. a. Note: investigational therapies used as part of clinical care, (eg, remdesivir, hydroxychloroquine) are permissible.

Treatment and study plan

COVID-19 Convalescent Plasma

Biological

Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.

Primary outcomes

  1. Participants With Serious Adverse Events.

    Time frame: Up to Study Day 29

    Cumulative incidence of participants with at least one serious adverse events (SAEs) at Study Day 29.

  2. Time to Clinical Improvement.

    Time frame: Up to Study Day 29

    Time to removal from mechanical ventilation.

Secondary outcomes

  1. Clinical Status Assessment, Using 8-point Ordinal Scale, of Convalescent Plasma Administration

    Time frame: Up to Study Day 29

    Time to improvement by at least 2 category from Day 1 (time to reach WHO8 <=5). WHO8 score:

    • Not hospitalized, no limitations on activities.
    • Not hospitalized, limitation on activities and/or requiring home oxygen;
    • Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;
    • Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise);
    • Hospitalized, requiring supplemental oxygen;
    • Hospitalized, on non-invasive ventilation or high flow oxygen devices;
    • Hospitalized, on invasive mechanical ventilation or ECMO;
    • Death

  2. Clinical Status Assessment Using the National Early Warning Score (NEWS) of Convalescent Plasma Administration

    Time frame: Up to Study Day 29

    Time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.

    NEWS assessed daily while hospitalized until discharge or death and on Days 15 and 29.

    Higher NEWS is worse, range from 0 to 20.

  3. Incidence of New Oxygenation Use up to Day 29 of Convalescent Plasma Administration

    Time frame: From enrollment to Day 29.

    Incidence of new oxygenation use up to Day 29.

  4. Duration of New Oxygen Use up to Day 29 of Convalescent Plasma Administration

    Time frame: From enrollment to Day 29.

    Days of new oxygen use up to Day 29.

  5. Oxygenation

    Time frame: Daily while hospitalized up to Study Day 29.

    Days of supplemental oxygen while in hospital up to Study Day 29. In hospital supplemental oxygen days counted as days with a WHO8 ordinal score of 5, 6, or 7.

  6. Non-invasive Ventilation/High Flow Oxygen Days up to Day 29 of Convalescent Plasma Administration.

    Time frame: Daily while in hospital to Study Day 29.

    Days of non-invasive ventilation/high flow oxygen while in hospital up to Day 29, defined as having WHO8 ordinal score of 6 = Hospitalized, on non-invasive ventilation or high flow oxygen devices

  7. Number of Subjects With at Least One Day of Non-invasive Ventilation/High Flow Oxygen up to Day 29 of Convalescent Plasma Administration.

    Time frame: Daily while in hospital to Study Day 29.

    Number of subjects with at least one day of non-invasive ventilation (WHO8 ordinal score of 6) while in hospital

  8. Duration of Non-invasive Ventilation/High Flow Oxygen up to Day 29 of Convalescent Plasma Administration.

    Time frame: Daily while in hospital to Study Day 29.

    Days of non-invasive ventilation/high flow oxygen up to Day 29.

  9. Invasive Ventilation/ Extracorporeal Membrane Oxygenation(ECMO) Days

    Time frame: Daily while in hospital to Study Day 29

    Days on Invasive Ventilator/ECMO defined as WHO8 ordinal score of 7 = Hospitalized, on invasive mechanical ventilation or ECMO

  10. Incidence of New Mechanical Ventilation or ECMO Use of Convalescent Plasma Administration.

    Time frame: From enrollment to Day 29.

    Incidence of new mechanical ventilation or ECMO use up to Day 29.

  11. Duration of New Mechanical Ventilation or ECMO Use of Convalescent Plasma Administration.

    Time frame: From enrollment to Day 29.

    Days of new mechanical ventilation or ECMO use up to Day 29.

  12. Duration of Hospitalization

    Time frame: To Study Day 29

    Duration (days) of first hospitalization. Time until death or discharge or Study Day 29

  13. Mortality

    Time frame: 28 days from Study Day 1

    28 day mortality

  14. Serious Adverse Events (SAEs) Through Day 29 of Convalescent Plasma Administration.

    Time frame: Through Study Day 29.

    subjects with Serious Adverse Events (SAEs) through Day 29.

  15. Number of Subjects With at Least One Grade 3 and Grade 4 Clinical and/or Laboratory Adverse Events Through Day 29 of Convalescent Plasma Administration.

    Time frame: Through Study Day 29

    Number of subjects with at least one Grade 3 or Grade 4 clinical and/or laboratory adverse events through Day 29.

  16. Changes in WBC With Differential Through Day 29 of Convalescent Plasma Administration.

    Time frame: Through Day 29.

    Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value > baseline lab value.

  17. Changes in Hemoglobin Measurement Through Day 29 of Convalescent Plasma Administration.

    Time frame: Through Day 29.

    Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value > baseline lab value.

  18. Changes in Platelets Measurement Through Day 29 of Convalescent Plasma Administration.

    Time frame: Through Day 29.

    Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value > baseline lab value.

  19. Changes in Creatinine Measurement Through Day 29 of Convalescent Plasma Administration.

    Time frame: Through Day 29.

    Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value > baseline lab value.

  20. Changes in Glucose Measurement Through Day 29 of Convalescent Plasma Administration.

    Time frame: Through Day 29.

    Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value > baseline lab value.

  21. Changes in Total Bilirubin Measurement Through Day 29 of Convalescent Plasma Administration.

    Time frame: Through Day 29.

    Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value > baseline lab value.

  22. Changes in ALT Measurement Through Day 29 of Convalescent Plasma Administration.

    Time frame: Through Day 29.

    Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value > baseline lab value.

  23. Changes in AST Measurement Through Day 29 of Convalescent Plasma Administration.

    Time frame: Through Day 29

    Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value > baseline lab value.

  24. Changes in PT Measurement Through Day 29 of Convalescent Plasma Administration.

    Time frame: Through Day 29

    Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value > baseline lab value.

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Official study title

An Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
May 14, 2020
Registry last updated
Apr 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.